Treatment of refractory melasma with combination of topical 5% magnesium ascorbyl phosphate and fluorescent pulsed light in Asian patients
Background Melasma is an acquired disorder of hypermelanosis of great psychosocial concern. The treatments with various conventional therapies are often unsatisfactory. Lasers and light sources have been used to treat pigmented lesions, but in Asian skin with higher melanin content, such treatments...
Gespeichert in:
Veröffentlicht in: | International journal of dermatology 2014-01, Vol.53 (1), p.93-99 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background
Melasma is an acquired disorder of hypermelanosis of great psychosocial concern. The treatments with various conventional therapies are often unsatisfactory. Lasers and light sources have been used to treat pigmented lesions, but in Asian skin with higher melanin content, such treatments may be challenging.
Objectives
To determine the effectiveness of treating melasma with a combination of topical 5% magnesium ascorbyl phosphate (MAP) and fluorescent pulsed light (FPL).
Materials and methods
Patients of skin types III–V with refractory melasma were treated for 12 weeks with topical application of 5% MAP and three sessions of FPL (570–950 nm) at 3, 6, and 9 weeks (fluence 12–14 J/cm2, pulse width 15 ms, and spot size 3 cm2). They were followed up for another 12 weeks to assess the persistence of treatment benefit. Digital photographs of the patients were taken at each visit. Treatment efficacy was determined by calculating mean melasma area and severity index (MASI) at the beginning and then at weeks 6, 12, and 24. The subjective assessment was done by comparing pre‐treatment and post‐treatment photographs by an independent observer and self‐assessment by patients using four‐point scoring scale (1, poor, 2, fair, 3, good, and 4, excellent).
Results
Sixty‐five patients completed the study. The baseline mean MASI score of 14.80 decreased to 4.53 at the 12th week (end of treatment) and 6.35 at the 24th week (end of follow‐up). The overall regression of mean MASI at these end‐points was 69.3% and 57% (P |
---|---|
ISSN: | 0011-9059 1365-4632 |
DOI: | 10.1111/ijd.12195 |